Lewis Asset Management LLC Sells 530 Shares of Novo Nordisk A/S (NYSE:NVO)

Lewis Asset Management LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 9.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,942 shares of the company’s stock after selling 530 shares during the period. Lewis Asset Management LLC’s holdings in Novo Nordisk A/S were worth $425,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S in the second quarter worth about $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $42,000. Albion Financial Group UT boosted its position in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares during the period. Finally, Sound Income Strategies LLC grew its stake in shares of Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after acquiring an additional 243 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $84.05 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The stock’s fifty day simple moving average is $94.75 and its 200 day simple moving average is $114.02. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The firm has a market cap of $377.17 billion, a price-to-earnings ratio of 27.20, a P/E/G ratio of 0.90 and a beta of 0.45.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.